Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess
the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in
ovarian cancer (OC) patients with oligometastatic progression (OMP) after first maintenance
therapy with any PARP inhibitor. A total of 30 patients with OC and OMP will be enrolled and
will receive treatment with niraparib 300 or 200 mg, according to body weight or platelet
count. Patients will start treatment within 6 weeks after surgery and will receive it until
progressive disease or treatment discontinuation. The main purpose of the study is to
evaluate progression-free survival (PFS) of niraparib rechallenge in OC patients with OMP and
no residual disease after secondary cytoreductive surgery.